SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GENZYME - THE KING OF THE BIOTECHS
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: H. Bradley Toland, Jr. who wrote (328)7/30/1998 12:39:00 PM
From: aliveinsf  Read Replies (2) of 410
 
I was careless when I said 10 years, I was writing from memory and not data in front of me when I made the comment. The point is, over a six or seven year period of time management has failed to deliver results which were promised at the time the bios were rallying. Compared to AMGN and BGEN, whose returns, while not stellar, are certainly higher and better than GENZ. Thus, GENZ has been a poor investment, due entirely to management setting expectations which did not materialize. The financial games that HENRI tries to play only adds confusion.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News